Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ibuprofen 200mg / Phenylephrine 5mg tablets
0310000Q0AAACAC
|
Phenylephrine hydrochloride (Decongestant) | Phenylephrine hydrochloride | Respiratory System | No data available |
|
Ibuprofen 200mg / Phenylephrine 6.1mg tablets
1001010J0AABSBS
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ibuprofen 200mg effervescent tablets
1001010J0AABPBP
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ibuprofen 300mg modified-release / Codeine 20mg tablets
1001010J0AAARAR
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ibuprofen 5% cream
1003020P0AAAAAA
|
Ibuprofen (Topical Antirheumatic) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ibuprofen 5% foam
1003020P0AAAFAF
|
Ibuprofen (Topical Antirheumatic) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ibuprofen 800mg tablets
1001010J0AAAGAG
|
Ibuprofen (NSAID) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ibuprofen lysine 400mg oral powder sachets
1001010ADAAADAD
|
Ibuprofen lysine | Ibuprofen lysine | Musculoskeletal and Joint Diseases | No data available |
|
Ibutop Ralgex Ibuprofen 5% gel
1003020P0BIAAAC
|
Ralgex (Ibuprofen) | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Icatibant 30mg/3ml inj pre-filled syringes
0304030H0AAAAAA
|
Icatibant acetate | Icatibant acetate | Respiratory System | No data available |
|
Ichthammol 1% / Clioquinol 3% in Hydrocortisone 1% ointment
1304000V0AAEWEW
|
Hydrocortisone (Topical) | Hydrocortisone | Skin | No data available |
|
Ichthammol 10% in Yellow soft paraffin
1305010J0AAAYAY
|
Ichthammol (Topical) | Ichthammol | Skin | No data available |
|
Ichthammol 13% in Yellow soft paraffin
1305010J0AAAUAU
|
Ichthammol (Topical) | Ichthammol | Skin | No data available |
|
Ichthammol 2% in Hydrocortisone 1% ointment
1304000V0AAELEL
|
Hydrocortisone (Topical) | Hydrocortisone | Skin | No data available |
|
Ichthammol 5% in Hydrocortisone 1% ointment
1304000V0AAEMEM
|
Hydrocortisone (Topical) | Hydrocortisone | Skin | No data available |
|
Ichthammol 7% in Yellow soft paraffin
1305010J0AAASAS
|
Ichthammol (Topical) | Ichthammol | Skin | No data available |
|
Ichthammol 8% in Yellow soft paraffin
1305010J0AAAXAX
|
Ichthammol (Topical) | Ichthammol | Skin | No data available |
|
Ichthammol 9% in Yellow soft paraffin
1305010J0AAAWAW
|
Ichthammol (Topical) | Ichthammol | Skin | No data available |
|
Ichthammol glycerin liquid
1305010J0AAADAD
|
Ichthammol (Topical) | Ichthammol | Skin | No data available |
|
Ichthammol liquid 1% in Clobetasone 0.05% ointment
1304000H0AACICI
|
Clobetasone butyrate (Topical) | Clobetasone butyrate | Skin | No data available |
|
Iclusig 15mg tablets
0801050BQBBAAAA
|
Iclusig | Ponatinib | Malignant Disease and Immunosuppression | No data available |
|
Iclusig 30mg tablets
0801050BQBBACAC
|
Iclusig | Ponatinib | Malignant Disease and Immunosuppression | No data available |
|
Iclusig 45mg tablets
0801050BQBBABAB
|
Iclusig | Ponatinib | Malignant Disease and Immunosuppression | No data available |
|
Ictastan 200mg/245mg tablets
0503010AABCAAAA
|
Ictastan | Emtricitabine and tenofovir disoproxil | Infections | No data available |
|
Idacio 40mg/0.8ml solution for injection pre-filled pens
1001030S0BGABAB
|
Idacio | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.